menu
    • menu

    Company profile for Cessation Therapeutics

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cessation is developing novel immunobiologics to prevent fentanyl overdose and to treat fentanyl addiction using a new approach: by sequestering fentanyl before it is able to enter the brain to offer durable protection from overdose. There are no current FDA-approved products aimed at protecting from fentanyl overdose, which is essential to curb the dramatic rise in overdose deaths. Fentanyl kills within minutes of exposure t...
    Cessation is developing novel immunobiologics to prevent fentanyl overdose and to treat fentanyl addiction using a new approach: by sequestering fentanyl before it is able to enter the brain to offer durable protection from overdose. There are no current FDA-approved products aimed at protecting from fentanyl overdose, which is essential to curb the dramatic rise in overdose deaths. Fentanyl kills within minutes of exposure to a lethal dose, far faster than heroin or prescription opioids, which renders current treatments, such as Narcan, ineffective.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cessation TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3210 Merryfield Row San Diego, CA 92121
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cessationtherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Products Expo

    Natural Products Expo

    Not Confirmed

    envelop Contact Supplier

    Natural Products Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cessation Therapeutics Presents Findings From Anti-Fentanyl Study
    Cessation Therapeutics Presents Findings From Anti-Fentanyl Study

    19 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240619579616/en

    BUSINESSWIRE
    19 Jun 2024
    Share Share
    Cessation Therapeutics Receives FDA Fast Track Designation for CSX-1004
    Cessation Therapeutics Receives FDA Fast Track Designation for CSX-1004

    31 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231031071512/en

    BUSINESSWIRE
    31 Oct 2023
    Share Share
    Cessation Awarded $14.8 Million Grant from the National Institute of Drug Abuse
    Cessation Awarded $14.8 Million Grant from the National Institute of Drug Abuse

    18 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231018223510/en

    BUSINESSWIRE
    18 Oct 2023
    Share Share
    Dr. Vince Clinical Research Joins the Fight Against the Fentanyl Crisis, Announces Screening of First Subject for Cessation Therapeutics’ Overdose Prevention Therapy in a First-In-Human Trial
    Dr. Vince Clinical Research Joins the Fight Against the Fentanyl Crisis, Announces Screening of First Subject for Cessation Therapeutics’ Overdose Prevention Therapy in a First-In-Human Trial

    02 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230802123498/en

    BUSINESSWIRE
    02 Aug 2023
    Share Share
    Cessation Announces FDA Authorization for First-in-Human Trial of Antibody
    Cessation Announces FDA Authorization for First-in-Human Trial of Antibody

    27 Jul 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230727978075/en

    BUSINESSWIRE
    27 Jul 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search